Amgen Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Amgen Inc. (AMGN) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$9.00 million for the 12-month period ending 2015-12-31, per its 8-K filed 2016-10-31.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2016-10-31
- Amgen Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2013 was $41.00M, a 72.11% decline from fiscal 2012.
- Amgen Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2012 was $147.00M, a 219.57% increase from fiscal 2011.
- Amgen Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2011 was $46.00M.
- Amgen Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2010 was -$12.00M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2015-12-31 | -$9.00M 8-K · filed 2016-10-31 | |
| 2014-12-31 | $22.00M 8-K · filed 2016-10-31 | |
| 2013-12-31 | $41.00M 10-K · filed 2015-02-19 | |
| 2012-12-31 | $147.00M 10-K · filed 2014-02-24 | |
| 2011-12-31 | $46.00M 10-K · filed 2013-02-27 | |
| 2010-12-31 | -$12.00M 10-K · filed 2012-02-29 | $12.00M 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |